MindMed (MNMD.Q) announced they are appointing Dr. Maurizio Fava to their Scientific Advisory Board. Dr. Fava obtained his medical doctorate from the University of Padova School of Medicine, and went…
MMED.NEO
Mind Medicine (MNMD.Q) announced the addition of Dr. Peter Bergethon to their Scientific Advisory Board. Bergethon is a “world-leading” expert in neurology, digital medicine, and central nervous system (CNS)…
Mind Medicine (MMED.NE) announced the publication of the first pharmacogenetic data on LSD to help personalize dosing. The study results from a pooled secondary analysis of four Phase I…
Street cred MindMed (MMED.NEO) announced last fall it was applying to be listed on the Nasdaq Exchange. MindMed would be the first Canadian psychedelics company listed on a major…
“The truth is that everyone is bored, and devotes himself to cultivating habits.” – Albert Camus, The Plague E-commerce For decades companies have invested billions trying to understand consumer behavior,…
MindMed (MMED.NE) announced the publication of the first study on MDMA dosing optimisation using personalised medicine. The study was conducted at the University Hospital Basel Liechti Lab, in Basel,…
“Life is too short to be small.” – Tim Ferriss, The 4-Hour Workweek Every psychedelics company starts its investor deck off with a fact about the quickly changing regulatory…
Mind Medicine (MMED.E) announced today their intended acquisition of digital medicine and therapeutics start-up, Healthmode, according to a press release. The acquisition brings access to HealthMode’s intellectual property, as…
Mind Medicine (MMED.E) announced earlier this week their intention to conduct a randomized placebo-controlled study using LSD to evaluate certain health and cognitive effects according to a press release….
Shroom BOOM! MindMed has been one of the talk on the street, with price jumping over 50% this month and market cap exceeding 1 Billion! Shroom stocks have been…